TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05417191

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fish
Description: Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enriched fish
Description: Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.
Study: NCT01431391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 45.0 mg depot injection, 2 doses 6 months apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 45.0 mg depot injection, 2 doses 6 months apart
Study: NCT03931694

Intervention type: DEVICE
Intervention: e-DOL
Description: e-health program (smartphone and web platform)
Study: NCT04367090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, trastuzumab
Description: Docetaxel and trastuzumab once per cycle
Study: NCT03204448

Intervention type: DEVICE
Intervention: BioCLIA Ro60
Description: BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL

Intervention type: DEVICE
Intervention: BioCLIA Ro60
Description: BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
Study: NCT04367090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400/320 mg orally daily
Study: NCT04083157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccine with imiquimod
Description: Intradermal hepatitis B vaccine with topical imiquimod pretreatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular hepatitis B vaccine with aqueous cream
Description: Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
Study: NCT00963066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PSV - pressure suppot ventilation
Description: Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA - Neurally Adjusted Ventilatory Assist
Description: Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA - EMG
Description: Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
Study: NCT01061801

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional expression
Description: Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional expression
Description: Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional expression
Description: Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
Study: NCT03348618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Intravenous immunoglobulin
Study: NCT02368418

Intervention type: PROCEDURE
Intervention: PCP
Description: PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).

Intervention type: PROCEDURE
Intervention: PCP
Description: PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).

Intervention type: PROCEDURE
Intervention: SRS
Description: SRS is short for a community-based Salt Reduction program delivered by community health educators.

Intervention type: PROCEDURE
Intervention: SRS
Description: SRS is short for a community-based Salt Reduction program delivered by community health educators.
Study: NCT00739063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
Study: NCT00425763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQAS
Description: AQAS dosed by body weight, on days 0, 1, 2
Study: NCT01570114

Intervention type: DEVICE
Intervention: Fully covered metallic colonic stent
Description: Endoscopically insertion of fully covered metallic colonic stent
Study: NCT01509274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: 3 ml plasma injected once into the plantar fascia

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 3 ml of saline injected once into the plantar fascia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy + heel cap
Description: Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
Study: NCT00931645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Description: TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DHAP rescue and Autologous stem cell transplantation
Description: DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DHAP rescue and F+C
Description: DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) \& cyclophosphamide (300 mg/sqm)
Study: NCT01587287

Intervention type: DEVICE
Intervention: Corneal power measurement
Description: All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
Study: NCT02658760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine plus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: dexmedetomidine and Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: dexmedetomidine and Bupivacaine
Study: NCT02792920

Intervention type: DEVICE
Group type: OTHER
Intervention: CoCr-EES
Study: NCT03242525

Intervention type: DIAGNOSTIC_TEST
Intervention: POCT and central laboratory blood analysis
Description: In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.

Intervention type: DIAGNOSTIC_TEST
Intervention: POCT and central laboratory blood analysis
Description: In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
Study: NCT00743717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zirconia femoral component
Description: total knee arthroplasty performed using implant with zirconia femoral component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cobalt chrome femoral component
Description: total knee arthroplasty performed using implant with cobalt chrome femoral component
Study: NCT01516918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: tablet, 400-mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa-2a
Description: subcutaneous injection, 180-mcg, once weekly
Study: NCT01478373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258)
Description: Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
Study: NCT03560128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff Vision device
Description: Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmplifEYE device
Description: Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
Study: NCT00919126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Air in Oxygen
Description: Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
Study: NCT01108380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma pheresis, Right portal vein embolization
Description: Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma pheresis, Right portal vein embolization
Description: Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plasma pheresis, Right portal vein embolization
Description: Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam.
Study: NCT01734759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taste Test
Description: Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg
Study: NCT03450265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
Study: NCT00637494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone
Description: 1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
Study: NCT03028116

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study: NCT01301729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
Study: NCT02537691

Intervention type: DRUG
Group type: OTHER
Intervention: FP
Description: ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.

Intervention type: DRUG
Group type: OTHER
Intervention: LABA
Description: LABA will be administered as per investigator discretion.

Intervention type: DRUG
Group type: OTHER
Intervention: LTRA
Description: LTRA will be administered as per investigator discretion.

Intervention type: DRUG
Group type: OTHER
Intervention: LAMA
Description: LAMA will be administered as per investigator discretion.

Intervention type: DRUG
Group type: OTHER
Intervention: Theophylline
Description: Theophylline will be administered as per investigator discretion.
Study: NCT03450265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tachosil
Description: Applied according to the current instruction for use (IFU).
Study: NCT02537691

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Corticosteroids
Description: Oral corticosteroids will be administered as per investigator discretion.
Study: NCT04151043

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suggestions
Description: Verbal suggestions or no suggestions about treatment outcome

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suggestions
Description: Verbal suggestions or no suggestions about treatment outcome

Intervention type: DEVICE
Group type: OTHER
Intervention: Deep brain stimulation
Description: Regulation of deep brain stimulation intensity

Intervention type: DEVICE
Group type: OTHER
Intervention: Deep brain stimulation
Description: Regulation of deep brain stimulation intensity
Study: NCT02996773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: After transplant, given intravenously on day +4 as part of Phase Ib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: After transplant, given intravenously on day +3 as part of Phase 1b.
Study: NCT04317092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection
Description: Tocilizumab 8 mg/kg (up to a maximum of 800mg per dose). A second administration (same dose) can be given after 12 hours if respiratory function has not recovered, at discretion of the Investigator.
Study: NCT01920529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aerobic exercise
Description: Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
Study: NCT00971373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestagen scrubs
Description: antimicrobial impregnated textile
Study: NCT01372748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPR
Description: 30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous chest compressions
Description: Continuous chest compressions during the first 6 minutes of the resuscitation.
Study: NCT01281605

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active titration algorithm
Description: Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\<110mg/dl).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual titration algorithm
Description: All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG\>=110mg/dL, and by 4 IU/day if the FPG\>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \< 70 mg/dL.
Study: NCT01377818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ventilation
Description: positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: excecise training
Description: The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~* 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~* Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Both
Description: both types of intervention
Study: NCT04197778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055 tablet
Description: DDO-3055 tablet, 2 single doses separated by 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055 tablet
Description: DDO-3055 tablet, 2 single doses separated by 6 days.
Study: NCT04327011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511 vector
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
Description: Toca FC is an extended-release formulation of flucytosine.
Study: NCT00262665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORG 24448
Description: flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
Study: NCT02964312

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal Implant
Description: Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
Study: NCT01295398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nebulisations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nebulisations

Intervention type: DEVICE
Group type: OTHER
Intervention: nebulisations